These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16925750)

  • 81. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
    D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
    J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition.
    Stephenson AJ; Kattan MW; Eastham JA; Dotan ZA; Bianco FJ; Lilja H; Scardino PT
    J Clin Oncol; 2006 Aug; 24(24):3973-8. PubMed ID: 16921049
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
    Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy.
    Ahove DA; Hoffman KE; Hu JC; Choueiri TK; D'Amico AV; Nguyen PL
    Urology; 2010 Nov; 76(5):1201-5. PubMed ID: 20709376
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Prognostic value of surgical margin status for biochemical recurrence following radical prostatectomy.
    Hashimoto K; Masumori N; Takei F; Fukuta F; Takahashi A; Itoh N; Hasegawa T; Tsukamoto T
    Jpn J Clin Oncol; 2008 Jan; 38(1):31-5. PubMed ID: 18203710
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy.
    Eisenberg ML; Davies BJ; Cooperberg MR; Cowan JE; Carroll PR
    Eur Urol; 2010 Apr; 57(4):622-9. PubMed ID: 19375843
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Does the molecular staging in pelvic lymph nodes improve the detection of relevant prostate cancer metastases? An assessment after 6 years.
    Schostak M; Krause H; Miller K; Schrader M; Kempkensteffen C; Kollermann J
    BJU Int; 2007 Jun; 99(6):1409-14. PubMed ID: 17428244
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Prostate specific antigen levels in the follow up of localised prostate cancer: how does radiotherapy compare to radical prostatectomy?
    Ziade J; Leprise ES; Bansard JY; Patard JJ; Lobel B; Guille F
    Prostate Cancer Prostatic Dis; 1999 May; 2(3):155-158. PubMed ID: 12496825
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Poor agreement of prostate specific antigen doubling times calculated using ultrasensitive versus standard prostate specific antigen values: important impact on risk assessment.
    Reese AC; Fradet V; Whitson JM; Davis CB; Carroll PR
    J Urol; 2011 Dec; 186(6):2228-32. PubMed ID: 22014796
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The biologic lower detection limit of six ultrasensitive PSA assays.
    Junker R; Brandt B; Semjonow A; Erren M; Zechel C; Assmann G
    Anticancer Res; 1999; 19(4A):2625-8. PubMed ID: 10470206
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Detectable serum PSA after radical prostatectomy. Clinical and pathological relevance of perianastomotic biopsies.
    Minardi D; Galosi AB; Dell'Atti L; Yehia M; Muzzonigro G
    Anticancer Res; 2004; 24(2C):1179-85. PubMed ID: 15154644
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Kinetics of tumor growth of prostate carcinoma estimated using prostate-specific antigen.
    Truskinovsky AM; Partin AW; Kroll MH
    Urology; 2005 Sep; 66(3):577-81. PubMed ID: 16140081
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Surgery for localized prostate cancer after renal transplantation.
    Hafron J; Fogarty JD; Wiesen A; Melman A
    BJU Int; 2005 Feb; 95(3):319-22. PubMed ID: 15679786
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Local recurrence after radical prostatectomy for prostatic cancer].
    Viville C
    Ann Urol (Paris); 2000 Feb; 34(1):53-7. PubMed ID: 10763425
    [TBL] [Abstract][Full Text] [Related]  

  • 95. PSA recurrence: definitions, PSA kinetics, and identifying patients at risk.
    Klotz LH
    Can J Urol; 2006 Apr; 13 Suppl 2():43-7. PubMed ID: 16672128
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Adjuvant radiation therapy for recurrent PSA after radical prostatectomy in T1-T2 prostate cancer.
    Ravery V; Lamotte F; Hennequin CH; Toublanc M; Boccon-Gibod L; Hermieu JF; Delmas V; Boccon-Gibod L
    Prostate Cancer Prostatic Dis; 1998 Dec; 1(6):321-325. PubMed ID: 12496874
    [TBL] [Abstract][Full Text] [Related]  

  • 97. PSA course after definitive high-dose radiotherapy of localized prostate cancer.
    Schüller P; Schäfer U; Micke O; Panke JE; Willich N
    Anticancer Res; 2005; 25(3A):1555-7. PubMed ID: 16033060
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A prostate-specific antigen-like protein associated with renal cell carcinoma in women.
    Clements J; Ward G; Kaushal A; Hi SI; Kennett C; Nicol D
    Clin Cancer Res; 1997 Aug; 3(8):1427-31. PubMed ID: 9815828
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence.
    Skove SL; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Moreira DM; Freedland SJ
    Urology; 2017 Oct; 108():129-134. PubMed ID: 28735016
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001).
    Van Poppel H; Vekemans K; Da Pozzo L; Bono A; Kliment J; Montironi R; Debois M; Collette L
    Eur J Cancer; 2006 May; 42(8):1062-7. PubMed ID: 16624554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.